A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta variants
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Several vaccines have been introduced to combat the coronavirus infectious disease‐2019 (COVID‐19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Current SARS‐CoV‐2 vaccines include mRNA‐containing lipid nanoparticles or adenoviral vectors that encode the SARS‐CoV‐2 Spike (S) protein of SARS‐CoV‐2, inactivated virus, or protein subunits. Despite growing success in worldwide vaccination efforts, additional capabilities may be needed in the future to address issues such as stability and storage requirements, need for vaccine boosters, desirability of different routes of administration, and emergence of SARS‐CoV‐2 variants such as the Delta variant. Here, we present a novel, well‐characterized SARS‐CoV‐2 vaccine candidate based on extracellular vesicles (EVs) of Salmonella typhimurium that are decorated with the mammalian cell culture‐derived Spike receptor‐binding domain (RBD). RBD‐conjugated outer membrane vesicles (RBD‐OMVs) were used to immunize the golden Syrian hamster ( Mesocricetus auratus ) model of COVID‐19. Intranasal immunization resulted in high titres of blood anti‐RBD IgG as well as detectable mucosal responses. Neutralizing antibody activity against wild‐type and Delta variants was evident in all vaccinated subjects. Upon challenge with live virus, hamsters immunized with RBD‐OMV, but not animals immunized with unconjugated OMVs or a vehicle control, avoided body mass loss, had lower virus titres in bronchoalveolar lavage fluid, and experienced less severe lung pathology. Our results emphasize the value and versatility of OMV‐based vaccine approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688 · cited 1×
“…Delta variant, exosomes INTRODUCTION The coronavirus infectious disease-2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Wu et al., 2020; Zhu et al., 2020), has highlighted the need for rapid vaccine development capabilities (Shang et al., 2020).”
BackgroundThéry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099 · cited 7×
“Gram-negative bacteria such as Salmonella typhimurium produce EVs known as outer membrane vesicles (OMVs).”
MethodInfluentialSelf-citationEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101544 · Cited by 2,397 · cited 1×
“Several of the available vaccines have elicited remarkable protection against disease (Baden et al., 2021; Sadoff et al., 2021), and worldwide vaccination efforts have achieved tremendous successes in many countries.”
BackgroundEvaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024671 · Cited by 1,066
The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines
Shang, W., Yang, Y., Rao, Y., & Rao, X. (2020) · npj Vaccines · doi:10.1038/s41541-020-0170-0 · Cited by 275
Tenforde, M. W., Self, W. H., Naioti, E. A., Ginde, A. A., Douin, D. J., Olson, S. M., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7034e2 · Cited by 204
Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2020) · doi:10.1101/2020.09.08.280818 · Cited by 126 · cited 1×
“Current SARS-CoV-2 vaccines consist ofmRNA-containing lipid nanoparticles or adenoviral vectors that encode the surface Spike (S) protein of SARS-CoV-2 (Corbett et al., 2020; Tostanoski et al., 2020; Vogel, 2020).”
Background
Cited by
The roles of extracellular vesicles in the immune system
Buzas, E. I. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00763-8 · Cited by 1,220
Synergistic vesicle-vector systems for targeted delivery
Marquez, C. A., Oh, C.-I., Ahn, G., Shin, W.-R., Kim, Y.-H., & Ahn, J.-Y. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02275-6 · Cited by 37
Metadata
- Authors
- Jiang, L., Driedonks, T. A. P., Jong, W. S. P., Dhakal, S., Bart van den Berg van Saparoea, H., Sitaras, I., Zhou, R., Caputo, C., Littlefield, K., Lowman, M., Chen, M., Lima, G., Gololobova, O., Smith, B., Mahairaki, V., Riley Richardson, M., Mulka, K. R., Lane, A. P., Klein, S. L., Pekosz, A., Brayton, C., Mankowski, J. L., Luirink, J., Villano, J. S., & Witwer, K. W.
- Venue
- Journal of Extracellular Vesicles
- Publisher
- Wiley
- Published
- 2022-03
- Volume
- 11
- Issue
- 3
- Pages
- e12192-e12192
- ISSN
- 2001-3078 (ISSN-L)
- OpenAlex
- W4220870024
- Cited by
- 166
- References
- 8
- FWCI
- 17.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta variants. https://app.cochat.ai/papers/10.1002/jev2.12192
- The paper
- Jiang, L., Driedonks, T. A. P., Jong, W. S. P., Dhakal, S., Bart van den Berg van Saparoea, H., Sitaras, I., Zhou, R., Caputo, C., Littlefield, K., Lowman, M., Chen, M., Lima, G., Gololobova, O., Smith, B., Mahairaki, V., Riley Richardson, M., Mulka, K. R., Lane, A. P., Klein, S. L., . . . Witwer, K. W. (2022). A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta variants. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.12192
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.